Filing Details

Accession Number:
0000904454-16-001172
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-04-21 17:12:17
Reporting Period:
2016-04-19
Filing Date:
2016-04-21
Accepted Time:
2016-04-21 17:12:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1403708 Evoke Pharma Inc EVOK () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1013425 I Jesse Treu C/O Domain Associates, Llc
One Palmer Square
Princeton NJ 08542
No No Yes No
1024000 C James Blair C/O Domain Associates, Llc
One Palmer Square
Princeton NJ 08542
No No Yes No
1196863 Nicole Vitullo C/O Domain Associates, Llc
One Palmer Square
Princeton NJ 08542
No No Yes No
1207786 H Brian Dovey C/O Domain Associates, Llc
One Palmer Square
Princeton NJ 08542
No No Yes No
1354718 K Brian Halak C/O Domain Associates, Llc
One Palmer Square
Princeton NJ 08542
No No Yes No
1372932 Dp Vii Associates Lp C/O Domain Associates, Llc
One Palmer Square
Princeton NJ 08542
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-04-19 632 $5.36 16,366 No 4 S Direct
Common Stock Disposition 2016-04-20 76 $5.29 16,290 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC ("OPSA VII"), the sole general partner of the Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
  3. As managing members of OPSA VII, which is also the sole general partner of Domain Partners VII, L.P. each Reporting Owner listed below may also be deemed to indirectly beneficially own 955,498 shares of Common Stock held by Domain Partners VII, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VII, L.P., however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
  4. As managing members of Domain Associates, LLC, each Reporting Owner listed below may also be deemed to indirectly beneficially own 5,250 shares of Common Stock held by Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Associates, LLC, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.